Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘-mabs’?

IF 5.4 2区医学 Q1 ONCOLOGY

The Journal of Pathology Pub Date : 2026-09-15 Epub Date: 2026-07-08 DOI:10.1002/path.70095

Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli

{"title":"Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘-mabs’?","authors":"Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli","doi":"10.1002/path.70095","DOIUrl":null,"url":null,"abstract":"<p>Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone-sensitive PCa to metastatic castration-resistant PCa. For this reason, other therapeutic strategies, including immunotherapy, are being investigated. Despite initial enthusiasm, these approaches have not yet produced significant improvements in either progression free survival or overall survival. Several factors may have contributed to the consistently disappointing results of immune checkpoint inhibitors in PCa, despite their more successful results in other tumor types. In this review, we discuss the potential reasons for these disappointing clinical results. © 2026 The Author(s). <i>The Journal of Pathology</i> published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.</p>","PeriodicalId":232,"journal":{"name":"The Journal of Pathology","volume":"270 2","pages":"139-162"},"PeriodicalIF":5.4000,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/path.70095","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Pathology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/path.70095","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone-sensitive PCa to metastatic castration-resistant PCa. For this reason, other therapeutic strategies, including immunotherapy, are being investigated. Despite initial enthusiasm, these approaches have not yet produced significant improvements in either progression free survival or overall survival. Several factors may have contributed to the consistently disappointing results of immune checkpoint inhibitors in PCa, despite their more successful results in other tumor types. In this review, we discuss the potential reasons for these disappointing clinical results. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

查看原文本刊更多论文

免疫检查点抑制剂在前列腺癌中的无效：这仅仅是一个“单抗”的问题吗？

前列腺癌（PCa）是第二常见的肿瘤类型，目前有多种治疗药物。尽管在过去的十年中，治疗的进步提高了总生存率，但晚期前列腺癌患者最终会从激素敏感型前列腺癌发展为转移性去势抵抗型前列腺癌。因此，正在研究包括免疫疗法在内的其他治疗策略。尽管最初热情高涨，但这些方法尚未在无进展生存期或总生存期方面产生显著改善。尽管免疫检查点抑制剂在其他肿瘤类型中的效果更成功，但其在前列腺癌中的效果却一直令人失望，这可能是由几个因素造成的。在这篇综述中，我们讨论了这些令人失望的临床结果的潜在原因。©2026作者。《病理学杂志》由John Wiley & Sons Ltd代表大不列颠和爱尔兰病理学会出版。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The Journal of Pathology 医学-病理学

CiteScore

14.10

自引率

1.40%

发文量

144

审稿时长

3-8 weeks

期刊介绍： The Journal of Pathology aims to serve as a translational bridge between basic biomedical science and clinical medicine with particular emphasis on, but not restricted to, tissue based studies. The main interests of the Journal lie in publishing studies that further our understanding the pathophysiological and pathogenetic mechanisms of human disease. The Journal of Pathology welcomes investigative studies on human tissues, in vitro and in vivo experimental studies, and investigations based on animal models with a clear relevance to human disease, including transgenic systems. As well as original research papers, the Journal seeks to provide rapid publication in a variety of other formats, including editorials, review articles, commentaries and perspectives and other features, both contributed and solicited.